Welcome New Corporate Partners: Adaptive Biotechnologies, Retrophin, Intercept Pharmaceuticals, Cognizant Technology Solutions, Charles River Associates

Please join us in welcoming the following new corporate partners contributing their support to the HBA mission.


Adaptive Biotechnologies 
CEO: Chad Robins
Adaptive Biotechnologies is a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. The company’s proprietary immune medicine platform enables product applications across life sciences research, clinical diagnostics, and drug discovery.


CEO: Eric Dube, Ph.D.
Biopharmaceutical company dedicated to identify, develop and deliver life-changing therapies to people living with a rare disease.

Intercept Pharmaceuticals 
CEO: Mark Pruzanski
Company description: Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.


Cognizant Technology Solutions 
CEO: Brian Humphries
Cognizant is an American multinational corporation that provides IT services, including digital, technology, consulting and operations services. It is headquartered in Teaneck, New Jersey, U.S. Cognizant is part of the NASDAQ-100 and trades under CTSH.


Charles River Associates 
President & CEO: Paul Maleh
With proven skills in complex cases and exceptional strength in analytics, CRA consultants have provided astute guidance to clients in thousands of successful engagements. We offer litigation and regulatory support, business strategy and planning, market and demand forecasting, policy analysis and risk management consulting services.


Interested in becoming a corporate partner? Explore the value of partnership with the HBA and view the latest packages.